After a median follow-up of @ months ( IQR @-@ ) , progression-free survival was longer in the afatinib group than in the methotrexate group ( median @ months -LSB- @ % CI @-@ -RSB- for the afatinib group vs @ months -LSB- @-@ -RSB- for the methotrexate group ; hazard ratio -LSB- HR -RSB- @ -LSB- @ % CI @-@ -RSB- , p = @ ) .